Kenvue Inc. (NYSE:KVUE) Holdings Decreased by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank reduced its position in shares of Kenvue Inc. (NYSE:KVUE) by 0.3% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 477,727 shares of the company’s stock after selling 1,512 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Kenvue were worth $11,050,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of KVUE. Leo Wealth LLC grew its holdings in shares of Kenvue by 0.3% in the 3rd quarter. Leo Wealth LLC now owns 151,611 shares of the company’s stock worth $3,507,000 after acquiring an additional 481 shares during the last quarter. Massmutual Trust Co. FSB ADV increased its position in Kenvue by 6.2% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 8,400 shares of the company’s stock worth $194,000 after purchasing an additional 492 shares during the last quarter. Wolff Wiese Magana LLC raised its holdings in Kenvue by 0.7% during the third quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company’s stock valued at $1,781,000 after buying an additional 501 shares in the last quarter. Marathon Capital Management lifted its holdings in Kenvue by 0.3% in the 2nd quarter. Marathon Capital Management now owns 149,699 shares of the company’s stock worth $2,722,000 after purchasing an additional 514 shares during the last quarter. Finally, Poehling Capital Management INC. raised its position in shares of Kenvue by 0.5% in the second quarter. Poehling Capital Management INC. now owns 104,934 shares of the company’s stock valued at $1,908,000 after purchasing an additional 547 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Stock Performance

KVUE stock opened at $24.08 on Friday. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The firm has a market cap of $46.17 billion, a PE ratio of 43.78, a P/E/G ratio of 2.19 and a beta of 1.36. The business’s 50-day moving average price is $22.94 and its two-hundred day moving average price is $20.99.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The business had revenue of $3.90 billion for the quarter, compared to analysts’ expectations of $3.92 billion. During the same quarter in the previous year, the business posted $0.31 EPS. Kenvue’s revenue for the quarter was down .4% on a year-over-year basis. As a group, research analysts forecast that Kenvue Inc. will post 1.07 earnings per share for the current year.

Kenvue Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th were issued a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 3.41%. The ex-dividend date was Wednesday, November 13th. Kenvue’s dividend payout ratio (DPR) is presently 149.09%.

Analyst Ratings Changes

KVUE has been the topic of several research analyst reports. JPMorgan Chase & Co. raised their price objective on shares of Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. UBS Group raised their price target on shares of Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. Jefferies Financial Group initiated coverage on Kenvue in a report on Tuesday, September 24th. They issued a “buy” rating and a $27.00 target price for the company. Royal Bank of Canada downgraded Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 target price for the company. in a research report on Tuesday, September 24th. Finally, Piper Sandler boosted their price target on shares of Kenvue from $20.00 to $21.00 and gave the company a “neutral” rating in a research report on Monday, September 23rd. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $22.64.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.